Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time

American Heart Journal

Volumn 140, Issue 4, 2000, Pages 637-642

  Bozovich, G E ^a   Gurfinkel, E P ^a   Antman, E M ^a   McCabe, C H ^a   Mautner, B ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0033815295     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.109921     Document Type: Article

References (16)

1. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome
2. Antithrombotic agents in coronary disease
3. A comparison of low molecular weight heparin versus unfractionated heparin for unstable coronary artery disease
4. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
5. Dose ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
6. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Resutts of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
7. Unfractionated heparin in acute coronary syndromes: Has its time come and gone?
8. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
9. Time activation of acute thrombotic markers in patients developing or not developing silent ischemia in the framework of unstable angina
10. Heparin
11. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
12. Heparin enhances platelet aggregation irrespective of anticoagulation with citrate or with hirudin
13. Rebound increase in thrombin generation and activity after cessation of intravenaus heparin in patients with acute coronary syndromes
14. Low-molecular weight heparins. Are they different?